ARTICLE | Emerging Company Profile
Karuna team, backers reunite for neuropsychiatry play Seaport’s launch
PureTech’s Zohar, Karuna’s Paul among team advancing prodrug candidates for anxiety and depression that avoid hepatic absorption
April 9, 2024 9:54 PM UTC
With Karuna’s $14 billion acquisition in the rearview and its schizophrenia treatment nearing FDA approval, a group of the biotech’s investors and team has come back together to launch Seaport, a start-up advancing prodrugs intended to treat neuropsychiatric disorders while avoiding side effects including liver toxicity.
Seaport Therapeutics Inc. debuted with $100 million in a series A round from PureTech Health plc (LSE:PRTC; NASDAQ:PRTC), Arch Venture Partners and Sofinnova Investments, all of which backed Karuna Therapeutics Inc. Third Rock Ventures is also a Seaport investor...